Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 1/2016

01-01-2016 | Chronic Daily Headache (SJ Wang, Section Editor)

Update on the Pharmacological Treatment of Chronic Migraine

Authors: Christina Sun-Edelstein, Alan M. Rapoport

Published in: Current Pain and Headache Reports | Issue 1/2016

Login to get access

Abstract

Chronic migraine (CM) is a common and disabling disorder that remains underdiagnosed and poorly treated. Significant unmet therapeutic needs add to the burden of this disorder; even when CM is recognized, effective treatment options are limited and randomized controlled trials supporting the use of various preventive medications are sparse. In this review, we discuss the available options for CM treatment. Currently the only FDA-approved treatment for CM prevention is onabotulinumtoxinA. Two double-blind studies have demonstrated the efficacy of topiramate for CM prevention, but it is not FDA-approved for this indication. Treatments in development for migraine will also be reviewed. Advancements in the understanding of migraine pathogenesis have identified new targets for both acute and preventive treatment and have engendered the development of targeted and mechanism-based therapies. The need for more effective treatment for CM patients, which has long since been identified, is now being addressed. Several of the emerging treatments for migraine prevention are under investigation specifically for CM or high-frequency episodic migraine.
Literature
1.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition (beta version). Cephalalgia. 2013;33:629–808.CrossRef
2.
Natoli JL, Manack A, Dean B, Butler Q, Turket CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609.PubMed
3.
Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–70.PubMedCrossRef
4.
Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301–15.PubMedCrossRef
5.
Payne KA, Varon SF, Kawata AK, et al. The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia. 2011;31:1116–30.PubMedCrossRef
6.
Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P. Psychiatric comorbiditiy in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain. 2009;10:283–90.PubMedPubMedCentralCrossRef
7.
8.
9.
10.
Sun-Edelstein C, Mauskop A. Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache. 2011;51:469–83.PubMedCrossRef
11.
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–68.PubMedCrossRef
12.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.PubMedCrossRef
13.
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–88.PubMedCrossRef
14.
Hepp Z, Bloudek LM, Varon SF, et al. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20:22–33.PubMed
15.
Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–66.PubMedCrossRef
16.
Diener H-C, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.PubMedCrossRef
17.
Silberstein SC, Lipton RD, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80.PubMedCrossRef
18.
Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9:37–41.PubMedPubMedCentralCrossRef
19.
Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache; a randomized, placebo-controlled study. Neurology. 2003;61:1753–9.PubMedCrossRef
20.
Saper JR, Lake III AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;2:470–82.CrossRef
21.
Couch JR. Amitriptyline versus placebo study group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51:33–51.PubMedCrossRef
22.
Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34:497–502.PubMedCrossRef
23.
Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33:35–9.PubMedCrossRef
24.
Bermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol. 2009;32:103–6.PubMedCrossRef
25.
Pascual-Gomez J, Gracia-Naya M, Leira R, et al. Zonisamide in the preventive treatment of refractory migraine. Rev Neurol. 2010;50:129–32.PubMed
26.
Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48:1337–42.PubMedCrossRef
27.
Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev. 2015;4, CD002919.
28.
Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006;122:315–25.PubMedCrossRef
29.
Aoki KR. Review of a proposed mechamism for the anti-nociceptvie action of botulinum toxin type A. Neurotoxicology. 2005;26(5):785–93.PubMedCrossRef
30.•
Ashenazi A, Blumenthal A. OnabotulinumtoxinA for the treatment of headache. Headache. 2013;53 Suppl 2:53–61. Good review of onabotulinumtoxinA for headache treatment.
31.
Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.PubMedCrossRef
32.
Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.PubMedCrossRef
33.
Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.PubMedCrossRef
34.
Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1–2):48–56.PubMedCrossRef
35.
Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851–9.PubMedPubMedCentralCrossRef
36.
Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.PubMedCrossRef
37.
Silberstein SD, Dodick DW, Aurora SK, Diener HC, Degryse RE, Lipton RB, et al. Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neursurg Psychiatry. 2014;0:1–6.
38.
Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29:1021–7.PubMedCrossRef
39.
Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49:1153–62.PubMedCrossRef
40.
41.
Olesen J. Detoxification for medication overuse headache is the primary task. Cephalalgia. 2012;32:420–2.PubMedCrossRef
42.
Goldstein J, Smith T, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52:1402–10.PubMedCrossRef
43.
Djupesland PG, Docekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia. 2010;30(8):933–42.PubMed
44.
Cady R, McAllister P, Spierings E, et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (the TARGET study). Headache. 2015;55:88–100.PubMedPubMedCentralCrossRef
45.
Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, et al. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks. Headache. 2015;55:621–35.PubMedPubMedCentralCrossRef
46.
47.
Aurora S, Silberstein S, Kori S, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51:507–17.PubMedCrossRef
48.•
Goldberg SW, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;29:443–52. Comprehensive review of CGRP in migraine pathogenesis and as a novel therapeutic target. CrossRef
49.
Recober A, Russo AF. Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007;10(8):566–74.PubMed
50.
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10.PubMedCrossRef
51.
Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573–84.PubMedCrossRef
52.
Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30:1159–69.PubMedCrossRef
53.
Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol. 1996;50:219–23.PubMed
54.
Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–13.PubMedCrossRef
55.
56.
57.
Johnson KW, Nisenbaum ES, Johnson MP, et al. Innovative drug development for headache disorders: glutamate. In: Olesen J, Ramadan N, editors. Innovative drug development for headache disorders, Frontiers in headache research, vol. 16. New York: Oxford University Press; 2008. p. 185–94.CrossRef
58.
Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80:642–7.PubMedCrossRef
59.
60.
61.
62.
Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885–92.PubMedCrossRef
63.
Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–7.PubMedCrossRef
64.
Goadsby PJ, Dodick DW, Martinez J, Ferguson M, Oakes T, Tanaka Y, et al. Onset of efficacy of LY2951742 in migraine prevention: Data from a Phase 2a, randomized, double-blind, placebo-controlled study of a monoclonal antibody to calcitonin gene-related peptide (a post-hoc analysis). Unpublished data, presented at: 57th Annual Scientific Meeting of the American Headache Society, Washington, DC, June 2015.
65.
Dodick DW, Goadsby PJ, Ferguson M, Oakes T, Tanaka Y, Ni X, et al. Sustained response outcomes from a Phase 2a, randomized, double-blind, placebo-controlled study of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a post-hoc analysis. Unpublished data, presented at: 57th Annual Scientific Meeting of the American Headache Society, Washington, DC, June 2015.
66.
67.
Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia. 2014;34:483–92.CrossRef
68.
Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings ELH, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091–100.
69.
Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine; a multicentre, randomised, double-blind, placebo-controlled phase 2b study. Lancet Neurol. 2015;14(11):1081–90.
70.
Bigal M, Rapoport A, Tepper S, Ma M, Silberstein S. TEV-48125 for the preventive treatment of chronic migraine—efficacy at early time points. Unpublished data, presented at: 57th Annual Scientific Meeting of the American Headache Society, Washington, DC, June 2015.
71.
Lenz R, Silberstein S, Dodick D, Reuter U, Ashina M, Saper J, et al. Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine. Unpublished data, presented at: 17th Congress of the International Headache Society, Valencia, May 2015.
72.
Laursen JC, Cairns BE, Kumar U, Somvanshi RK, Dong XD, Arendt-Nielsen L, et al. Nitric oxide release from trigeminal satellite glial cells is attenuated by glial modulators and glutamate. Int J Physiol Pathophysiol Pharmacol. 2013;5(4):228–38.PubMedPubMedCentral
73.
74.
75.
76.
Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med. 2007;13:1483–9.PubMedCrossRef
77.
Holland PR, Akerman S, Andreou AP, Karsan N, Wemmie JA, Goadsby PJ. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol. 2012;72:559–63.PubMedCrossRef
Metadata
Title
Update on the Pharmacological Treatment of Chronic Migraine
Authors
Christina Sun-Edelstein
Alan M. Rapoport
Publication date
01-01-2016
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 1/2016
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-015-0533-9

Other articles of this Issue 1/2016

Current Pain and Headache Reports 1/2016 Go to the issue

Childhood and Adolescent Headache (S Evers, Section Editor)

Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update

Chronic Daily Headache (SJ Wang, Section Editor)

Outcome of Chronic Daily Headache or Chronic Migraine

Chronic Daily Headache (SJ Wang, Section Editor)

Psychological Therapy in Adolescents with Chronic Daily Headache

Chronic Daily Headache (SJ Wang, Section Editor)

Update of Inpatient Treatment for Refractory Chronic Daily Headache

Childhood and Adolescent Headache (S Evers, Section Editor)

Pediatric Aspects of Headache Classification in the International Classification of Headache Disorders—3 (ICHD-3 beta version)

Chronic Daily Headache (SJ Wang, Section Editor)

Recent Approaches and Development of Acupuncture on Chronic Daily Headache